EQS News: Marinomed Biotech AG / Key word(s): Contract Marinomed Biotech AG concludes new sales partnerships for Carragelose in the Gulf region and Eastern Europe March 26, 2024 / 07:45 CET/CEST The issuer / publisher is responsible for the content of the announcement . ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════ Marinomed Biotech AG concludes new sales partnerships for Carragelose in the Gulf region and Eastern Europe • Specialist for the Gulf region GAIA Healthcare FZ LLC receives license for the marketing of Carragelose nasal sprays • Expansion of Carragelose partner network in Eastern Europe with VitaPlus Kft. Korneuburg, Austria, March 26, 2024 – Marinomed Biotech AG (VSE:MARI) has entered into partnerships with GAIA Healthcare FZ LLC and VitaPlus Kft for the distribution of Carragelose nasal sprays. GAIA Healthcare, a renowned pharmaceutical marketing and distribution company based in the United Arab Emirates, has secured the rights to market two different Carragelose nasal sprays in the Gulf region. GAIA will be responsible for obtaining regulatory approvals in the respective countries and plans a possible market launch in 2025 at the earliest. In addition, Marinomed has expanded its reach in selected Eastern European countries by entering into a distribution partnership with VitaPlus, a leading Hungarian pharmaceutical company owned by the Belgian Ceres Pharma, expanded. VitaPlus is active in the development and distribution of innovative and affordable branded nutritional supplements and medical products in Hungary and beyond. VitaPlus brands such as Medistus® are well-known among Hungarian pharmacists and consumers and are available in Hungarian pharmacies and drugstores. VitaPlus is already pushing ahead with the market launch and marketing of a nasal spray containing Carragelose and is planning the first sale for 2024. “By adding renowned and reliable partners such as GAIA and VitaPlus to our Carragelose sales network, we are following our strategy to further expand our market presence expand and introduce additional products in existing markets. We will probably see the first sales from the partnership with VitaPlus this year due to existing official approvals in the EU,” says Andreas Grassauer, CEO of Marinomed. “Overall, we are satisfied with the development of our Carragelose business by expanding our geographical reach to interesting pharmaceutical markets such as the Gulf region and Eastern Europe. At the same time, we are also making steady progress with our new allergy and eye drop products as well as with our partner Procter & Gamble in the USA.” About GAIA Healthcare FZ LLC Gaia Healthcare was founded in 2016 to address unmet medical needs in the Gulf region. The aim is to offer pharmaceutical products and services based on a European model of technology-driven drug distribution with a first-mover advantage in the United Arab Emirates and neighboring Gulf States. Over the last three years, GAIA has worked with some of the most renowned European and Asian pharmaceutical manufacturers. During this time, GAIA has launched several innovative medicines, a range of different generics, clinical innovation medical devices and various OTC products that are valued by patients, doctors and pharmacists in the region. About VitaPlus Kft. VitaPlus is a leading Hungarian pharmaceutical company active in the development and distribution of innovative and affordable branded nutritional supplements and medical devices in Hungary and beyond. VitaPlus brands such as 1×1 Vitamin®, Innopharm® and Medistus® are well-known among Hungarian pharmacists and consumers and are available in Hungarian pharmacies, drugstores and grocery chains. In 2022, VitaPlus achieved sales of 9 million euros. VitaPlus is part of the Belgium-based Ceres Pharma group, which operates in 10 European countries, employs 600 people and has a turnover of 140 million euros. About Carragelose®: Carragelose® is a sulfated polymer from red algae with a unique, broad spectrum of virus-blocking activity. It is known to be a tolerated, effective and safe agent for the prevention and treatment of viral respiratory diseases. Several clinical and preclinical studies have shown that Carragelose® forms a protective layer on the mucous membrane that prevents viruses from infecting cells. Laboratory studies and clinical data have confirmed that Carragelose® can also prevent the transmission of SARS-CoV-2.^(1)(1),(2)(2) Marinomed holds the patent rights to Carragelose® and has approved Carragelose® for distribution in Europe, North America, Australia and other countries in Asia and Latin America. Marinomed’s Carragelose® portfolio of nasal sprays and throat products can be found at (3) https://www.carragelose.com/en/portfolio/launched-productsthe scientific publications on Carragelose® at (4) https://www.marinomed.com/de/publikationen/wissenschaftliche-publikationen.
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotechnology company with a growing development pipeline and globally marketed therapeutics. The company develops patent-protected, innovative products in the therapeutic areas of immunology and virology based on its Marinosolv® platform and the virus-blocking effect of Carragelose®. The Marinosolv® technology increases the solubility and bioavailability of poorly soluble active ingredients and is used to develop new therapeutics for indications in the area of autoreactive immune diseases. The Virology segment includes Carragelose®-based over-the-counter products for the prophylaxis and treatment of viral upper respiratory tract infections, partnered in more than 40 countries. The company is based in Korneuburg, Austria and is listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information: (5) https://www.marinomed.com.
Inquiry note Marinomed Biotech AG International media inquiries PR & IR: Lucia Ziegler Metrum Communications: Eva Ruppnig T: +43 2262 90300 158 T: +43 664 4065744 E-mail: (6)pr@marinomed.com E-mail: (8)marinomed@metrum.at E-mail: (7)ir@marinomed.com Disclaimer This press release contains forward-looking statements that are based on current views, expectations and forecasts of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described or otherwise expressed or implied by such statements. The current views, expectations and forecasts of the management of Marinomed Biotech AG are influenced by the context of such statements or words as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and Recognize “target”. Forward-looking statements speak only as of the date on which they are made. Marinomed Biotech AG undertakes no obligation to update, revise or revise any forward-looking statements contained in this press release, whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are brands of Marinomed AG. The brands are the property of Marinomed Biotech AG or are licensed out to partners in selected countries. (9)^(1) (10)https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article- IJGM (11)^(2) (12)https://www.marinomed.com/de/news/marinomed-biotech-ag-informs-about-positive-clinical-results-for-iota-carrageenan-nasal-spray-for -covid-19-prevention-1 ═════════════════════════════════════ ═════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════════════ 03/26/2024 CET/CEST Publication of a corporate news/financial announcement, transmitted by EQS Group AG. www.eqs.com
═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════ Language: German Company: Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria Telephone: +43 2262 90300 Email: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6 WKN: A2N9MM Stock exchanges: open market in Berlin, Düsseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (official trading) EQS News ID: 1866707 End of announcement EQS News Service 1866707 March 26, 2024 CET/CEST References Visible links 1. file:///appl/crsred1/tmp/HTML-FormatExternal-3qLx4L.html#_edn1
2. file:///appl/crsred1/tmp/HTML-FormatExternal-3qLx4L.html#_edn2
3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=bd2a3dda556ab52fe6b2a10b732e7834&application_id=1866707&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=8970ab7396d4631147b0de7b43c3eb73&application_id=1866707&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=1866707&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
6. pr@marinomed.com 7. and@marinomed.com
8. marinomed@metrum.at
9. file:///appl/crsred1/tmp/HTML-FormatExternal-3qLx4L.html#_ednref1
10. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=33ccd3741e11d696674979569046f638&application_id=1866707&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
11. file:///appl/crsred1/tmp/HTML-FormatExternal-3qLx4L.html#_ednref2
12. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=c7c625ec75e8ba4c80a5a9176c5901e0&application_id=1866707&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news